02.08.2011 • NewsAlkermesBiotechnologyBilanz

Alkermes Q1 Loss Narrows Slightly

Integrated biotechnology company Alkermes, Monday reported net loss for the first quarter of $13.2 million, slightly narrower than the loss of $13.4 million in the year-ago quarter. Loss per share was unchanged at $0.14.

On average, 11 analysts polled by Thomson Reuters expected a loss of $0.12 per share for the quarter. Analysts' estimates typically exclude special items.

Results for the quarter included $5.7 million in share-based compensation expense and $9.5 million in costs related to the proposed merger with Elan Drug Technologies that is expected to close in September.

Excluding items, net income for the quarter was $1.9 million or $0.02 per share, compared to a net loss of $9.0 million or $0.09 per share last year.
Revenues for the quarter grew to $61.9 million from $42.3 million in the year-ago quarter. Ten Street analysts had a consensus revenue estimate of $52.7 million for the quarter.

 

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.